Skip to content
Film Television Auditions – Lifestyle
Author:
Medicus Pharma Ltd
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
June 11, 2026
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
June 8, 2026
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
June 3, 2026
Medicus Pharma Announces $22 Million Non-Dilutive Financing
May 28, 2026
←
Previous Page
1
2
3